BR0013590A - Composição para produzir uma mudança genética predeterminada em um gene cromossÈmico alvo de uma célula animal, métodos para se obter uma célula animal que contenha uma mudança genética predeterminada em um gene alvo, e de produzir uma mudança genética predeterminada em um tecido de um paciente mamìfero, composto para produzir uma mudança genética predeterminada - Google Patents
Composição para produzir uma mudança genética predeterminada em um gene cromossÈmico alvo de uma célula animal, métodos para se obter uma célula animal que contenha uma mudança genética predeterminada em um gene alvo, e de produzir uma mudança genética predeterminada em um tecido de um paciente mamìfero, composto para produzir uma mudança genética predeterminadaInfo
- Publication number
- BR0013590A BR0013590A BR0013590-9A BR0013590A BR0013590A BR 0013590 A BR0013590 A BR 0013590A BR 0013590 A BR0013590 A BR 0013590A BR 0013590 A BR0013590 A BR 0013590A
- Authority
- BR
- Brazil
- Prior art keywords
- genetic change
- predetermined genetic
- producing
- animal cell
- predetermined
- Prior art date
Links
- 230000002068 genetic effect Effects 0.000 title abstract 5
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 210000004102 animal cell Anatomy 0.000 title 2
- 230000002759 chromosomal effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 108091028664 Ribonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 210000003494 hepatocyte Anatomy 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000002336 ribonucleotide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Abstract
"COMPOSIçãO PARA PRODUZIR UMA MUDANçA GENéTICA PREDETERMINADA EM UM GENE CROMOSSÈMICO ALVO DE UMA CéLULA ANIMAL, MéTODOS PARA SE OBTER UMA CéLULA ANIMAL QUE CONTENHA UMA MUDANçA GENéTICA PREDETERMINADA EM UM GENE ALVO, E DE PRODUZIR UMA MUDANçA GENéTICA PREDETERMINADA EM UM TECIDO DE UM PACIENTE MAMìFERO, COMPOSTO PARA PRODUZIR UMA MUDANçA GENéTICA PREDETERMINADA". A invenção diz respeito à introdução de mudanças genéticas predeterminadas em genes alvo de uma célula viva, mediante introdução de um oligodeoxinucleotídeo codificando a mudança predeterminada. Os oligodeoxinucleotídeos são eficazes em células de animais, vegetais e bacterianas. São descritas modificações finais específicas que aumentam grandemente a eficácia dos oligodeoxinucleotídeos em bactérias. Surpreendentemente, oligodeoxinucleotídeos não modificados podem ser tão eficazes em células de mamíferos, incluindo hepatócitos in vivo, como os nucleotídeos modificados e podem ser tão eficazes ou mais eficazes do que os oligonucleotídeos quiméricos que consistem de uma mistura de deoxinucleotídeos e ribonucleotídeos 2'-O-metílicos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/384,960 US6271360B1 (en) | 1999-08-27 | 1999-08-27 | Single-stranded oligodeoxynucleotide mutational vectors |
| PCT/US2000/023457 WO2001015740A1 (en) | 1999-08-27 | 2000-08-25 | Single-stranded oligodeoxynucleotide mutational vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0013590A true BR0013590A (pt) | 2002-05-07 |
Family
ID=23519459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0013590-9A BR0013590A (pt) | 1999-08-27 | 2000-08-25 | Composição para produzir uma mudança genética predeterminada em um gene cromossÈmico alvo de uma célula animal, métodos para se obter uma célula animal que contenha uma mudança genética predeterminada em um gene alvo, e de produzir uma mudança genética predeterminada em um tecido de um paciente mamìfero, composto para produzir uma mudança genética predeterminada |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US6271360B1 (pt) |
| EP (3) | EP1210123B1 (pt) |
| JP (2) | JP5697187B2 (pt) |
| CN (1) | CN1384759B (pt) |
| AT (1) | ATE478687T1 (pt) |
| AU (2) | AU773242C (pt) |
| BR (1) | BR0013590A (pt) |
| CA (1) | CA2382120C (pt) |
| DE (1) | DE60044876D1 (pt) |
| DK (3) | DK2266627T3 (pt) |
| ES (3) | ES2544727T3 (pt) |
| NZ (1) | NZ517942A (pt) |
| PT (3) | PT2324856E (pt) |
| WO (1) | WO2001015740A1 (pt) |
| ZA (1) | ZA200201228B (pt) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6652607B2 (en) | 1999-07-07 | 2003-11-25 | The Lubrizol Corporation | Concentrated emulsion for making an aqueous hydrocarbon fuel |
| EP1212406A1 (en) * | 1999-08-20 | 2002-06-12 | University Of Delaware | Cell-free assay for plant gene targeting and conversion |
| US6271360B1 (en) * | 1999-08-27 | 2001-08-07 | Valigen (Us), Inc. | Single-stranded oligodeoxynucleotide mutational vectors |
| AR025996A1 (es) | 1999-10-07 | 2002-12-26 | Valigen Us Inc | Plantas no transgenicas resistentes a los herbicidas. |
| NZ521698A (en) * | 2000-03-27 | 2004-08-27 | Univ Delaware | Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| US6936467B2 (en) * | 2000-03-27 | 2005-08-30 | University Of Delaware | Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| EP1284985A2 (en) * | 2000-05-17 | 2003-02-26 | University Of Delaware | Plant gene targeting using oligonucleotides |
| WO2002010364A2 (en) * | 2000-07-27 | 2002-02-07 | University Of Delaware | Methods for enhancing targeted gene alteration using oligonucleotides |
| US7053195B1 (en) * | 2001-06-12 | 2006-05-30 | Syngenta Participatious Ag | Locked nucleic acid containing heteropolymers and related methods |
| CA2455424A1 (en) * | 2001-08-07 | 2003-02-20 | University Of Delaware | Compositions and methods for the prevention and treatment of huntington's disease |
| US20040096880A1 (en) * | 2001-08-07 | 2004-05-20 | Kmiec Eric B. | Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation |
| US7112405B2 (en) * | 2001-09-27 | 2006-09-26 | University Of Delaware | Compositions and methods for enhancing oligonucleotide-mediated gene alteration |
| EP1448766A2 (en) * | 2001-09-27 | 2004-08-25 | University Of Delaware | Coisogenic eukaryotic cell collections |
| AU2003220119A1 (en) * | 2002-03-07 | 2003-09-22 | University Of Delaware | Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea |
| GB0218803D0 (en) * | 2002-08-13 | 2002-09-18 | Nl Kanker I | Targeted gene modification by single-standed DNA oligonucleotides |
| US20040175722A1 (en) * | 2002-10-07 | 2004-09-09 | Kmiec Eric B. | Methods and compositions for reducing screening in oligonucleotide-directed nucleic acid sequence alteration |
| US6929917B2 (en) * | 2002-11-18 | 2005-08-16 | Pregentis | Method for cloning of a rare, specifically mutated cell |
| US20070072815A1 (en) * | 2004-05-04 | 2007-03-29 | Kmiec Eric B | Methods and kits to increase the efficiency of oligonucleotide-directed nucleic acid sequence alteration |
| UA99594C2 (en) | 2006-01-12 | 2012-09-10 | Сайбас Юроп Б.В. | Epsps mutants |
| US8029579B2 (en) | 2006-06-28 | 2011-10-04 | COH Inc. | Fatty acid blends and uses therefor |
| PL2177605T3 (pl) | 2006-10-06 | 2015-05-29 | Basf Plant Science Gmbh | Delta-5 desaturazy i sposób wytwarzania wielokrotnie nienasyconych kwasów tłuszczowych w organizmach transgenicznych innych niż człowiek |
| US9102948B2 (en) | 2006-11-17 | 2015-08-11 | 22Nd Century Limited, Llc | Regulating alkaloids |
| PL2700721T3 (pl) * | 2007-10-05 | 2019-06-28 | Cibus Europe B.V. | Zmutowane geny kodujące syntazę kwasu acetohydroksylowego w brassica |
| DK2234994T3 (da) * | 2007-12-27 | 2017-11-13 | Cibus Europe Bv | Fedtsyre-butylester-blandinger |
| AU2009248852B9 (en) | 2008-05-23 | 2015-08-13 | Cibus Europe B.V. | Production of squalene using yeast |
| CN103834675A (zh) | 2008-09-26 | 2014-06-04 | 巴斯夫农化产品有限公司 | 除草剂-抗性的ahas-突变体及使用方法 |
| EP2669380B1 (en) | 2008-12-12 | 2017-09-27 | BASF Plant Science GmbH | Desaturases and process for the production of polyunsaturated fatty acids in transgenic organisms |
| EP3219815B1 (en) * | 2009-11-23 | 2019-10-02 | Cibus Europe B.V. | Methods and compositions for producing squalene using yeast |
| UA112969C2 (uk) | 2010-08-03 | 2016-11-25 | Сібас Юс Ллс | Рослина, стійка до одного або більше ррх-інгібуючих гербіцидів, яка містить мутантний ген протопорфіриноген ix оксидази (ррх) |
| US20120122223A1 (en) | 2010-08-03 | 2012-05-17 | Cibus Us Llc | Mutated protoporphyrinogen ix oxidase (ppx) genes |
| WO2012028673A1 (en) | 2010-09-02 | 2012-03-08 | Ludwig-Maximilians-Universitaet Muenchen | Spontaneous organogenesis in plants |
| EP2426204A1 (en) | 2010-09-02 | 2012-03-07 | Ludwig-Maximilians-Universität München | Spontaneous nodule organogenesis in plants |
| KR101137285B1 (ko) | 2010-10-28 | 2012-04-20 | 위월드 주식회사 | 초소형 광대역 송수신 안테나 피더 |
| CN104662156A (zh) | 2012-08-17 | 2015-05-27 | 美国陶氏益农公司 | 玉米非翻译区域用于植物中转基因表达的用途 |
| WO2014153178A2 (en) | 2013-03-14 | 2014-09-25 | Cibus Us Llc | Mutated allene oxide synthase 2 (aos2) genes |
| US9957515B2 (en) | 2013-03-15 | 2018-05-01 | Cibus Us Llc | Methods and compositions for targeted gene modification |
| LT3527068T (lt) | 2013-03-15 | 2022-08-10 | Cibus Us Llc | Būdai ir kompozicijos, skirti padidinti tikslinės geno modifikacijos efektyvumą, panaudojant geno reparaciją, kuriai tarpininkauja oligonukleotidas |
| US12331303B2 (en) | 2013-03-15 | 2025-06-17 | Cibus Us Llc | Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair |
| PL2966984T3 (pl) | 2013-03-15 | 2022-06-13 | Cibus Us Llc | Ukierunkowana modyfikacja genu z użyciem naprawy genu, w której pośredniczy oligonukleotyd |
| ES2974625T3 (es) | 2014-03-14 | 2024-06-28 | Cibus Us Llc | Procedimientos y composiciones para aumentar la eficacia de la modificación génica dirigida mediante reparación génica mediada por oligonucleótidos |
| KR102841205B1 (ko) | 2016-02-09 | 2025-08-01 | 시버스 유에스 엘엘씨 | 올리고뉴클레오타이드 매개 유전자 보수를 사용한 표적화된 유전자 변형의 효율을 증가시키기 위한 방법 및 조성물 |
| US10584363B2 (en) | 2016-06-03 | 2020-03-10 | Takara Bio Usa, Inc. | Methods of producing and using single-stranded deoxyribonucleic acids and compositions for use in practicing the same |
| CN111819285B (zh) | 2018-01-09 | 2024-08-09 | 希博斯美国有限公司 | 防碎基因和突变 |
| AU2019247403B2 (en) | 2018-04-04 | 2025-04-10 | Cibus Europe, B.V. | FAD2 genes and mutations |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2731844B2 (ja) * | 1987-04-22 | 1998-03-25 | ザ・ユニヴァーシティー・オブ・コネチカット | 哺乳動物の細胞にポリヌクレオチドを導入するキャリア及び水溶性高分子複合体並びにその導入方法 |
| ES2099718T3 (es) * | 1990-07-02 | 1997-06-01 | Hoechst Ag | Analogos de oligonucleotidos con uniones internucleotidicas de 3'-3' o 5'-5' terminales. |
| AU681997B2 (en) | 1991-09-05 | 1997-09-18 | University Of Connecticut, The | Targeted delivery of poly- or oligonucleotides to cells |
| US5808044A (en) * | 1993-01-22 | 1998-09-15 | Pharmacia Biotech Inc. | Indocarbocyanine and benzindocarbocyanine phosphoramidites |
| US5556959A (en) | 1993-01-22 | 1996-09-17 | Pharmacia P-L Biochemicals Inc. | Indocarbocyanine-linked phosphoramidites |
| CN1048254C (zh) | 1993-12-09 | 2000-01-12 | 托马斯杰弗逊大学 | 用于将预定的改变引入靶基因中的化合物 |
| US5780296A (en) | 1995-01-17 | 1998-07-14 | Thomas Jefferson University | Compositions and methods to promote homologous recombination in eukaryotic cells and organisms |
| WO1996040271A1 (en) * | 1995-06-07 | 1996-12-19 | Yale University | Treatment of hemoglobinopathies |
| US5908777A (en) * | 1995-06-23 | 1999-06-01 | University Of Pittsburgh | Lipidic vector for nucleic acid delivery |
| FR2736926B1 (fr) | 1995-07-19 | 1997-08-22 | Rhone Poulenc Agrochimie | 5-enol pyruvylshikimate-3-phosphate synthase mutee, gene codant pour cette proteine et plantes transformees contenant ce gene |
| US5888983A (en) | 1996-05-01 | 1999-03-30 | Thomas Jefferson University | Method and oligonucleobase compounds for curing diseases caused by mutations |
| US5731181A (en) | 1996-06-17 | 1998-03-24 | Thomas Jefferson University | Chimeric mutational vectors having non-natural nucleotides |
| US5760012A (en) | 1996-05-01 | 1998-06-02 | Thomas Jefferson University | Methods and compounds for curing diseases caused by mutations |
| NZ337445A (en) * | 1997-02-26 | 2000-12-22 | Gen Hospital Corp | Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease |
| NZ500694A (en) | 1997-04-30 | 2001-09-28 | Univ Minnesota | Use of chimeric mutational vector (CMV), a macromolecule and a ligand for cell surface receptor adhesion molecule (clatherin) in gene therapy; the CMV vector derived from REC2 homologous pairing with Ustilago maydis |
| US6524613B1 (en) | 1997-04-30 | 2003-02-25 | Regents Of The University Of Minnesota | Hepatocellular chimeraplasty |
| GB9711015D0 (en) | 1997-05-28 | 1997-07-23 | Zeneca Ltd | Improvements in or relating to organic compounds |
| US5986086A (en) * | 1997-06-20 | 1999-11-16 | Amersham Pharmacia Biotech Inc. | Non-sulfonated cyanine dyes for labeling nucleosides and nucleotides |
| EP1007712A4 (en) | 1997-08-05 | 2004-06-30 | Kimeragen Inc | USE OF DUPLEX OLIGONUCLEOTIDES TO AFFECT LOCAL GENETIC CHANGES IN PLANTS |
| EP1032692A1 (en) | 1997-11-18 | 2000-09-06 | Pioneer Hi-Bred International, Inc. | Targeted manipulation of herbicide-resistance genes in plants |
| US6004804A (en) | 1998-05-12 | 1999-12-21 | Kimeragen, Inc. | Non-chimeric mutational vectors |
| US6271360B1 (en) * | 1999-08-27 | 2001-08-07 | Valigen (Us), Inc. | Single-stranded oligodeoxynucleotide mutational vectors |
| KR20170047291A (ko) | 2014-08-21 | 2017-05-04 | 코닝 인코포레이티드 | 적층 유리 제품에서 기포를 방지하는 방법 및 이로부터 형성된 적층 유리 제품 |
-
1999
- 1999-08-27 US US09/384,960 patent/US6271360B1/en not_active Expired - Lifetime
-
2000
- 2000-08-25 PT PT101839603T patent/PT2324856E/pt unknown
- 2000-08-25 ES ES10183960.3T patent/ES2544727T3/es not_active Expired - Lifetime
- 2000-08-25 EP EP00959442A patent/EP1210123B1/en not_active Expired - Lifetime
- 2000-08-25 DK DK10008602.4T patent/DK2266627T3/da active
- 2000-08-25 ES ES10008602.4T patent/ES2542530T3/es not_active Expired - Lifetime
- 2000-08-25 EP EP20100008602 patent/EP2266627B1/en not_active Expired - Lifetime
- 2000-08-25 AT AT00959442T patent/ATE478687T1/de active
- 2000-08-25 CN CN008149968A patent/CN1384759B/zh not_active Expired - Lifetime
- 2000-08-25 WO PCT/US2000/023457 patent/WO2001015740A1/en not_active Ceased
- 2000-08-25 ES ES00959442T patent/ES2358292T3/es not_active Expired - Lifetime
- 2000-08-25 PT PT00959442T patent/PT1210123E/pt unknown
- 2000-08-25 PT PT100086024T patent/PT2266627E/pt unknown
- 2000-08-25 NZ NZ517942A patent/NZ517942A/en not_active IP Right Cessation
- 2000-08-25 AU AU70767/00A patent/AU773242C/en not_active Expired
- 2000-08-25 CA CA2382120A patent/CA2382120C/en not_active Expired - Lifetime
- 2000-08-25 DE DE60044876T patent/DE60044876D1/de not_active Expired - Lifetime
- 2000-08-25 DK DK10183960.3T patent/DK2324856T3/en active
- 2000-08-25 BR BR0013590-9A patent/BR0013590A/pt not_active Application Discontinuation
- 2000-08-25 DK DK00959442.5T patent/DK1210123T3/da active
- 2000-08-25 EP EP20100183960 patent/EP2324856B1/en not_active Expired - Lifetime
- 2000-08-25 US US09/645,889 patent/US6479292B1/en not_active Expired - Lifetime
- 2000-08-25 JP JP2001520151A patent/JP5697187B2/ja not_active Expired - Lifetime
-
2002
- 2002-02-13 ZA ZA200201228A patent/ZA200201228B/en unknown
- 2002-11-12 US US10/292,856 patent/US7060500B2/en not_active Expired - Lifetime
-
2004
- 2004-08-19 AU AU2004205139A patent/AU2004205139B2/en not_active Expired
-
2012
- 2012-05-10 JP JP2012108528A patent/JP5813571B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1210123T3 (da) | Enkeltstrengede oligodeoxynucleotidvektorer egnede til mutation | |
| CN107787367B (zh) | 用于crispr/cas介导的基因调控的化学修饰的引导rna | |
| WO2019103442A3 (ko) | CRISPR/Cpf1 시스템을 이용한 유전체 편집용 조성물 및 이의 용도 | |
| EP2023939A4 (en) | COMPOUNDS AND METHOD FOR MODULATING THE EXPRESSION OF PCSK9 | |
| HRP20240657T1 (hr) | Materijali i postupci za liječenje hemoglobinopatija | |
| PT2143792E (pt) | Arn cíclico em cadeia simples, e método para a sua produção | |
| BR0209745A (pt) | Cromossomas artificiais de plantas, usos e dos mesmos e método para preparação de cromossomas artificiais de plantas | |
| JP2019520844A5 (pt) | ||
| CN107922949A (zh) | 用于通过同源重组的基于crispr/cas的基因组编辑的化合物和方法 | |
| EP0827410A4 (en) | METHOD FOR THE INTRODUCTION AND EXPRESSION OF GENES IN ANIMAL CELLS | |
| AR074672A1 (es) | Genes que codifican toxinas contra nematodos | |
| MX2010003891A (es) | Genes sinteticos que codifican cry1ac. | |
| AR061661A1 (es) | Gen de epsp sintetasa que confiere resistencia a herbicidas | |
| JP2022549519A (ja) | 標的化ヌクレアーゼを用いたマイクロバイオータ組成の調節 | |
| KR102679001B1 (ko) | 신규의 개량된 염기 편집 또는 교정용 융합단백질 및 이의 용도 | |
| DE60131101T2 (de) | pRNA-CHIMÄRE | |
| HUP0101961A2 (hu) | Az FSH-béta-gén módosítása homológ rekombinációval | |
| EP2527442A3 (en) | Compounds and methods for modulating gene expression | |
| EP1900815A3 (en) | In vivo production of small interfering RNAs that mediate gene silencing | |
| WO2004016749A3 (en) | Antisense modulation of acyl-coa synthetase 1 expression | |
| MXPA02004782A (es) | Genes del empequenecimiento del sorgo y metodos de uso. | |
| CN102899352A (zh) | 一种利用反义寡核苷酸沉默拟南芥内源miRNA的方法 | |
| Jansson et al. | Plant breeding: antisense ODN inhibition in in vitro spike cultures as a powerful diagnostic tool in studies on cereal grain development | |
| DE10200410A1 (de) | Antisense Oligodesoxynukleotid gegen das Pituitary-tumor transforming gene (PTTG) zur Hemmung der Translation in menschlichen Zellen | |
| CN115956417A (zh) | 一种阻控潮土硝态氮淋失的土壤微生物调控方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |